Contributions of BiosimilarBoaz

Contributions by BiosimilarBoaz, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,188 edits includes activity predating the current log.

1. 10:59, 18 Jun 2026 (diff | hist) Deamidation 5,263 ±0 m add the peptide-content point: area percent alone cannot give a mass
2. 19:31, 7 Mar 2026 (diff | hist) ISO 9001 4,278 ±0 m state that research-use-only labelling is a commercial category, not an approval
3. 09:50, 26 Feb 2026 (diff | hist) Talk:Patent expiry and biosimilars 400 +161 /* Impurities carry the application */ new section
4. 00:47, 8 Feb 2026 (diff | hist) Research use only 7,990 ±0 m attribute the compounding statement to the pharmacy board that issued it
5. 07:13, 11 Jan 2026 (diff | hist) Glucagon-like peptide-1 12,294 ±0 add category for receptor pharmacology
6. 11:03, 20 Jun 2025 (diff | hist) Active pharmaceutical ingredient 3,755 ±0 m attribute the compounding statement to the pharmacy board that issued it
7. 17:01, 20 Apr 2025 (diff | hist) Patent expiry and biosimilars 3,580 +369 attribute the compounding statement to the pharmacy board that issued it
8. 09:39, 5 Feb 2025 (diff | hist) Baseline laboratory panel 2,373 +36 convert the interval table to include both conventional and SI units
9. 18:44, 26 Jan 2025 (diff | hist) Bacterial endotoxin test 4,398 +296 add the note on co-elution and what it hides
10. 18:58, 7 Jan 2025 (diff | hist) Customs seizure 2,364 ±0 expand §Consequences for the material
11. 23:58, 1 Sep 2024 (diff | hist) Good manufacturing practice 1,153 ±0 m fix a broken wikilink